검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Elacestrant |
Overview Company | NYU Langone Health |
Overview Modality | ADC |
Overview Target | HER2 |
Overview Indication | ER Positive, HER2 Positive Breast Cancer |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | of oral SERDs compared with prior endocrine therapies and evaluates clinical evidence supporting their use across treatment settings in HR+/HER2- breast cancer |
MoA Biomarker | biomarkers and signaling pathways |
PK/PD Half-life | 50 h |
PK/PD Species | Rat |
PK/PD Animal (cat.) | Rat, In vitro |
PK/PD Experiment | TGI |
Toxicology Species | Rat |
Toxicology Animal (cat.) | Rat, In vitro |
Toxicology Major finding | A Computational Strategy to Identify Hub Genes in Pathway Analysis of Gamma Tocotrienol-treated MCF-7 Cells and Molecular Docking Study Using Selected Phytochemicals as Therapeutic Agents.. Breast cancer is a highly prevalent malignancy in women, necessitating the discovery of novel therapeutic approaches. Researchers have focused on various medicinal plants for their therapeutic benefits, includi… |
Clinical PFS | 3.78 |
Clinical OS | NA |
Clinical Result source | ClinicalTrials.gov NCT03778931 |
Clinical Data Tier / Score | A · 41 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Elacestrant |
Overview Company | NYU Langone Health |
Overview Modality | ADC |
Overview Target | HER2 |
Overview Indication | ER Positive, HER2 Positive Breast Cancer |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | of oral SERDs compared with prior endocrine therapies and evaluates clinical evidence supporting their use across treatment settings in HR+/HER2- breast cancer |
MoA Biomarker | biomarkers and signaling pathways |
PK/PD Half-life | 50 h |
PK/PD Species | Rat |
PK/PD Animal (cat.) | Rat, In vitro |
PK/PD Experiment | TGI |
Toxicology Species | Rat |
Toxicology Animal (cat.) | Rat, In vitro |
Toxicology Major finding | A Computational Strategy to Identify Hub Genes in Pathway Analysis of Gamma Tocotrienol-treated MCF-7 Cells and Molecular Docking Study Using Selected Phytochemicals as Therapeutic Agents.. Breast cancer is a highly prevalent malignancy in women, necessitating the discovery of novel therapeutic approaches. Researchers have focused on various medicinal plants for their therapeutic benefits, includi… |
Clinical PFS | 3.78 |
Clinical OS | NA |
Clinical Result source | ClinicalTrials.gov NCT03778931 |
Clinical Data Tier / Score | A · 41 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교